In-Vivo CAR T Update With Umoja Biopharma's David Fontana, Ph.D.
Business Of Biotech
00:00
The Competitive Landscape in the Cell CAR-T Space
There's probably a handful of competitors when I joined 18 months ago, and there were 20 companies I've never even heard of kind of in this almost exact identical space. What we're really looking to do and what we're trying to do effectively is a concept by called OPC, it's basically other people's cars. The second half of next year just excited to get that into the clinic and to explore patients. There's been some evidence now for the 170s of folate tag that there's been some nice data coming out of ADCs with immunogen,. So they'll be on the market and approve with an ADC. But the cell therapies just have a just a better attractive profile
Transcript
Play full episode
